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Chemical synthesis Chemical synthesis Chemical synthesis Chemical synthesis Scheme S1 Scheme S1 Scheme S1 Scheme S1 Reagents and Condition: i) PMBCl, TBAF, DMF, rt, 51%; ii) isoamyl nitrite, CH 2 I 2 , I 2 , CuI, THF, reflux, 96%; iii) TFA, reflux, 94%.
Materials and instrumentation
All reagents and solvents were purchased from Sigma-Aldrich (St. Louis, MO). 1 H NMR spectra were obtained with a Bruker 400 spectrometer using CDCl 3 and CD 3 OD as solvents. Chemical shifts are expressed in δ values (ppm) with tetramethylsilane (δ 0.00) for CDCl 3 and water (δ 3.30) for CD 3 OD. TLC analysis was carried out on glass sheets precoated with silica gel F254 (0.2 mm) from Aldrich. The purity of final nucleoside derivatives was checked using a Hewlett−Packard 1100 HPLC equipped with a Zorbax SB-Aq 5 µm analytical column (50 × 4.6 mm; Agilent Technologies Inc., Palo Alto, CA). Mobile phase: linear gradient solvent system, 5 mM TBAP (tetrabutylammonium dihydrogenphosphate)−CH 3 CN from 80:20 to 0:100 in 13 min; the flow rate was 0.5 mL/min. Peaks were detected by UV absorption with a diode array detector at 230, 254, and 280 nm. All derivatives tested for biological activity showed >95% purity by HPLC analysis (detection at 254 nm). Low-resolution mass spectrometry was performed with a JEOL SX102 spectrometer with 6-kV Xe atoms following desorption from a glycerol matrix or on an Agilent LC/MS 1100 MSD, with a Waters (Milford, MA) Atlantis C18 column. High resolution mass spectroscopic (HRMS) measurements were performed on a proteomics optimized Q-TOF-2 (Micromass-Waters) using external calibration with polyalanine, unless noted. Observed mass accuracies are those expected based on known performance of the instrument as well as trends in masses of standard compounds observed at intervals during the series of measurements. Reported masses are observed masses uncorrected for this time-dependent drift in mass accuracy. All of the monosubsituted alkyne intermediates were purchased from Sigma-Aldrich (St. Louis, MO), Small Molecules, Inc. (Hoboken, NJ), Anichem (North Brunswick, NJ), PharmaBlock, Inc. (Sunnyvale, CA), Frontier Scientific (Logan, UT) and Tractus (Perrineville, NJ).
7-Chloro-5-iodo-3H-imidazo[4,5-b]pyridine (5)
A solution of compound 40 (378, 0.94 mmol) in TFA (10 mL) was refluxed at 85 o C overnight. Solvent was evaporated and the residue was purified on flash silica gel column chromatography (CH 2 Cl 2 :MeOH = 20:1) to give compound 5 (248 mg, 94%) as a colorless powder. 1 DIAD (0.24 mL, 1.242 mmol) was added to a solution of triphenylphosphine (0.326 g, 1.242 mmol) and 1-deaza-2-iodo-6-chloropurine 5 (0.259 g, 0.926 mmol) in dry THF (3 mL) and the mixture stirred at room temperature for 10 min. A solution of compound 4 (0.150 g, 0.621 mmol) in THF (2 mL) was added to the reaction mixture, and the mixture stirred overnight at room temperature.
Solvent was evaporated and the residue was purified on flash silica gel column chromatography (hexane:ethyl acetate=4:1) to give compound 6 (0.160 g, 51%) as a colorless foam. 1 40% Methylamine solution (2.5 mL) was added to a solution of compound 6 (0.160, 0.318 mmol) in methanol (3 mL) and the mixture stirred at room temperature for 24 h. Solvent was evaporated under vacuum and the residue was purified on flash silica gel column chromatography (CH 2 Cl 2 :MeOH=40:1) to give compound 7 (0.111g, 72%) as a colorless foam. 1 Compound 8c (84%) was prepared from compound 7 following the same method for compound 8a. 1 Compound 9b (84%) was prepared from compound 8b following the same method for compound 9a. Compound 9c (89%) was prepared from compound 8c following the same method for compound 9a. Compound 9d (85%) was prepared from compound 8d following the same method for compound 9a. Compound 12 (83%) was prepared from compound 35b following the same method for compound 11. Compound 13 (86%) was prepared from compound 35c following the same method for compound 11. Compound 14 (80%) was prepared from compound 35d following the same method for compound 11. 
(1S,2R,3S,4R,5S)-4-(2-((5-chlorothiophen-2-yl)ethynyl)-6-(cyclopropylamino)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide (15)
Compound 15 (83%) was prepared from compound 35e following the same method for compound 11. 
(1S,2R,3S,4R,5S)-4-(2-((5-chlorothiophen-2-yl)ethynyl)-6-((cyclopropylmethyl)amino)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide (17)
Compound 17 (87%) was prepared from compound 35g following the same method for compound 11. Compound 18 (88%) was prepared from compound 35h following the same method for compound 11. 1 
(1S,2R,3S,4R,5S)-4-(5-((5-chlorothiophen-2-yl)ethynyl)-7-(methylamino)-3H-imidazo[4,5-b]pyridin-3-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide (19)
A solution of compound 9a (26 mg, 0.05 mmol) in methanol (2 mL) and 10% trifluromethane sulfonic acid (2 mL) was heated at 70 Compound 21 (87%) was prepared from compound 9c following the same method for compound 19. 1S,2R,3S,4R,5S)-4-(2-(4-(5-chlorothiophen-2-yl)-1H-1,2,3-triazol-1-yl)-6-((cyclopropylmethyl)amino)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide (25) 2-Chloro-5-ethynylthiophene (11.5 mg, 0.08 mmol) and TBTA (1 mg, 0.001 mmol) were added to a solution of compound 37g (23 mg, 0.057 mmol) in a mixture of t-butanol (1 mL) and water (1 mL). Subsequently freshly prepared 1M sodium ascorbate solution (58 µL, 0.05 mmol) followed by a 7.5% solution of copper sulfate (96 µL, 0.02 mmol) were added to the reaction mixture and the mixture stirred at room temperature overnight. Solvent was evaporated and the residue was purified on flash silica gel column chromatography (CH 2 (3aR,3bS,4aS,5R,5aS)-5-(5-(4-(5-chlorothiophen-2-yl)-1H-1,2,3-triazol-1-yl)-7-(propylamino)-3H-imidazo[4,5-b]pyridin-3-yl)-N,2,2-trimethyltetrahydrocyclopropa [3,4 
(3aR,3bS,4aS,5R,5aS)-5-(5-azido-7-(propylamino)-3H-imidazo[4,5-b]pyridin-3-yl)-N,2,2-trimethyltetrahydrocyclopropa[3,4]cyclopenta[1,2-d][1,3]dioxole-3b(3aH)-carboxamide (30)
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]cyclopenta[1,2-d][1,3]dioxole-3b(3aH)-carboxamide (31)
2-chloro-5-ethynylthiophene (6 mg, 0.042 mmol) and TBTA (1 mg, 0.001 mmol) were added to a solution of compound 30 (13mg, 0.03 mmol) in a mixture of t-butanol (1 mL) and water (1 mL). Subsequently freshly prepared 1M sodium ascorbate solution (31 µL, 0.03 mmol) followed by 7.5% solution of copper sulfate (51 µL, 0.015 mmol) were added to the reaction mixture and the mixture stirred at room temperature overnight. Solvent was evaporated and the residue was purified on flash silica gel column chromatography (CH 2 Cl 2 :MeOH = 35:1) to give compound 31 (15.4 mg, 89%) as a light yellow powder. 
Ethyl (3aR,3bS,4aS,5R,5aS)-5-(6-(ethylamino)-2-iodo-9H-purin-9-yl)-2,2-dimethyltetrahydrocyclopropa[3,4]cyclopenta[1,2-d][1,3]dioxole-3b(3aH)-carboxylate (33a)
Ethyl amine hydrochloride (0.122g, 1.5 mmol) and triethyl amine (0.5 mL, 2.99 mmol) were added to a solution of compound 32 (0.151g, 0.299 mmol) in anhydrous methanol (5 mL) and the mixture stirred at room temperature overnight. Solvent was evaporated under vacuum and residue was purified on flash silica gel column chromatography (hexane:ethylacetate=1:1) to give compound 33a (0.135g, 88%) as colorless foamy solid. 1 
Ethyl (3aR,3bS,4aS,5R,5aS)-5-(2-iodo-6-(propylamino)-9H-purin-9-yl)-2,2-dimethyltetrahydrocyclopropa[3,4]cyclopenta[1,2-d][1,3]dioxole-3b(3aH)-carboxylate (33b)
Compound 33b (73%) was prepared from compound 32 following the same method for compound 33a. 1 Ethyl (3aR,3bS,4aS,5R,5aS)-5-(6-(butylamino)-2-iodo-9H-purin-9-yl) 
Ethyl (3aR,3bS,4aS,5R,5aS)-5-(6-(cyclopropylamino)-2-iodo-9H-purin-9-yl)-2,2-dimethyltetrahydrocyclopropa[3,4]cyclopenta[1,2-d][1,3]dioxole-3b(3aH)-carboxylate (33e)
Compound 33e (82%) was prepared from compound 32 following the same method for compound 33a. 
Ethyl (3aR,3bS,4aS,5R,5aS)-5-(6-(cyclobutylamino)-2-iodo-9H-purin-9-yl)-2,2-dimethyltetrahydrocyclopropa[3,4]cyclopenta[1,2-d][1,3]dioxole-3b(3aH)-carboxylate (33f)
Compound 33f (84%) was prepared from compound 32 following the same method for compound 33a. 1 
Ethyl (3aR,3bS,4aS,5R,5aS)-5-(6-((cyclopropylmethyl)amino)-2-iodo-9H-purin-9-yl)-2,2-dimethyltetrahydrocyclopropa[3,4]cyclopenta[1,2-d][1,3]dioxole-3b(3aH)-carboxylate (33g)
Compound 33g (83%) was prepared from compound 32 following the same method for compound 33a. Ethyl (3aR,3bS,4aS,5R,5aS)-5-(6-((cyclobutylmethyl)amino)-2-iodo-9H-purin-9-yl)-2,2-dimethyltetrahydrocyclopropa[3,4]cyclopenta[1,2-d][1,3]dioxole-3b(3aH)-carboxylate (33h) Compound 33h (81%) was prepared from compound 32 following the same method for compound 33a. 1 (3aR,3bS,4aS,5R,5aS)-5-(2-iodo-6-(propylamino)-9H-purin-9-yl)-N,2,2-trimethyltetrahydro  cyclopropa[3,4]cyclopenta[1,2-d][1,3]dioxole-3b(3aH)-carboxamide (34b) Compound 34b (75%) was prepared from compound 33b following the same method for compound 34a. 1 (3aR,3bS,4aS,5R,5aS)-5-(6-(cyclopropylamino)-2-iodo-9H-purin-9-yl)-N,2,2-trimethyltetrahydrocyclopropa[3,4]cyclopenta[1,2-d][1,3]dioxole-3b(3aH)-carboxamide (34e) Compound 34e (74%) was prepared from compound 33e following the same method for compound 34a. 
(3aR,3bS,4aS,5R,5aS)-5-(6-((cyclopropylmethyl)amino)-2-iodo-9H-purin-9-yl)-N,2,2-trimethyltetrahydrocyclopropa[3,4]cyclopenta[1,2-d][1,3]dioxole-3b(3aH)-carboxamide (34g)
Compound 34g (74%) was prepared from compound 33g following the same method for compound 34a. 1 (3aR,3bS,4aS,5R,5aS)-5-(6-((cyclobutylmethyl)amino)-2-iodo-9H-purin-9-yl)-N,2,2-trimethyltetrahydrocyclopropa[3,4]cyclopenta[1,2-d][1,3]dioxole-3b(3aH)-carboxamide (34h) Compound 34h (76%) was prepared from compound 33h following the same method for compound 34a. Compound 35c (93%) was prepared from compound 34c following the same method for compound 35a. 1 Compound 35h (97%) was prepared from compound 34h following the same method for compound 35a. 1 (1S,2R,3S,4R,5S)-4-(6-((cyclopropylmethyl)amino)-2-iodo-9H-purin-9-yl)-2,3-dihydroxy-Nmethylbicyclo[3.1.0]hexane-1-carboxamide (36g) Compound 36g (91%) was prepared from compound 34g following the same method for compound 11. 1 -5-iodo-3-(4-methoxybenzyl)-3H-imidazo[4,5-b]pyridine (40) CuI (221 mg, 1.16 mmol), iodine (268 mg, 1.05 mmol), CH 2 I 2 (0.85 mL, 10.5 mmol) and isoamyl nitrite (0.42 mL, 3.17 mmol) were added to a solution of compound 39 (306 mg, 1.05 mmol) in dry THF (15 mL) and the mixture refluxed at 80 o C for 1 h. Water was added to the reaction mixture, and the aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with saturated sodium bisulfite solution followed by brine. The solution was dried (sodium sulfate), filtered and evaporated under vacuum. The residue was purified on flash silica gel column chromatography (hexane:ethyl acetate = 1:1) to give compound 40 (407 mg, 96%) as a colorless powder. 1 HPLC: Analytical purity checked using a Hewlett-Packard 1100 HPLC equipped with Zorbax SBAq 5 µm analytical column (150 × 4.6 mm; Agilent Technologies, Inc., Palo Alto, CA). Mobile phase: linear gradient solvent system: 0.1% TFA (trifuoroacetic acid)-CH 3 CN from 90:10 to 10:90 in 15 min; the flow rate was 1.0 mL/min. Peaks were detected by UV absorption with a diode array detector at 254, 275, and 280 nm. Purity of compounds tested for biological activity was at least 95% by HPLC.
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